section name header

Basics

Outline


BASICS

Definition!!navigator!!

Dermal fibroblast neoplasm with a minor epidermal component, with a variety of clinical forms. Often locally aggressive with a high propensity for recurrence after surgical excision, but does not metastasize.

Pathophysiology!!navigator!!

Incompletely characterized, complex, and multifactorial:

  1. BPV infection BPV infection potentially causal:
    • BPV DNA detected within fibroblast nuclei in most sarcoids, and at low levels in epidermis in some sarcoids (BPV-1 most commonly, also BPV-2, BPV-13, and horse-specific BPV-1 variants)
    • Viral proteins (e.g. oncoproteins E5, E7) consistently detected

      However, viral involvement unconfirmed:

    • BPV-1 DNA also detected in skin and blood of healthy horses
    • PV virions not detected via electron microscopy or virus isolation in sarcoids
    • BPV inoculation does not reproduce persistent disease
  2. Environmental factors also implicated
    • Epizootic disease outbreaks occur, with apparent transmission between horses
    • Insect transmission likely (identical BPV-1 DNA in sarcoids and flies in same regions)
    • Worldwide occurrence without seasonal or geographic predilection suggests other transmission routes (e.g. direct wound contact, indirect fomites)

Systems Affected!!navigator!!

Skin

Genetics!!navigator!!

Genetic susceptibility to sarcoids suspected, and a polygenic inheritance pattern proposed:

  • Higher risk in some breeds and families
  • Increased risk linked to MHC I genes (e.g. ELA-A3), MHC II genes (ELA-W13), and MHC II and non-MHC genes on ECA-20, ECA-22 (involved in host immune response)

Incidence/Prevalence!!navigator!!

Most common neoplasm of horses, with a prevalence of 1–12% reported, and accounting for 15–65% of all neoplasms, ahead of SCC, melanoma, and papilloma.

Geographic Distribution!!navigator!!

Worldwide

Signalment!!navigator!!

Breed Predilections

  • Higher risk—Quarter Horses; possibly Appaloosas, Arabians, and Thoroughbreds
  • Lower risk—Standardbreds

Mean Age and Range

  • Mean age—variable, suggested 3–9 years
  • Range—6 months to 15+ years

Predominant Sex

No gender predisposition.

Signs!!navigator!!

Historical Findings

Single or multiple lesions in a variety of body regions; may occur at sites of previous injury. May progress into more aggressive forms spontaneously.

Physical Examination Findings

  • Most frequent on the head (pinnae, lip margins, periocular), neck, lower limbs, and ventral body (inguinal, preputial, perineal)
  • Clinical forms are variable, and often mixed, including:
    1. Occult—focal, roughly circular, non-raised areas of alopecia with foci of scaling, lichenification, or papules. May start with subtle hair color/quality change. May be more common in relatively hairless body areas. May remain static for years, slowly enlarge, or progress to verrucous forms
    2. Verrucous (warty)—irregular papillomatous and scaly plaques to peduncles, often surrounded by a zone of mild lichenification with altered coat quality. May be less common on the limbs except for coronary band areas. Slow growing
    3. Nodular—firm, well-defined dermal or subcutaneous nodules of variable size (0.5–20 cm). May be solitary, or in small to occasionally myriad clusters. Predilection sites include inguinal, preputial, and periocular areas
    4. Nodular and ulcerated (“fibroblastic”)—irregularly nodular locally invasive lesions with prominent ulceration and exudation, often resembling exuberant granulation tissue (“proud flesh”). Fly worry, myiasis, and bacterial infections commonly complicate
    5. Malevolent—rare, invasive, irregularly nodular lesions that can infiltrate lymphatics and potentially local lymph nodes

Causes!!navigator!!

Likely caused by a complex association between BPV and inheritable traits of the horse, with environmental influences.

Risk Factors!!navigator!!

  • Suspected genetic and familial predispositions
  • Potential BPV transmission via flies, fomites, or direct wound contamination

Diagnosis

Outline


DIAGNOSIS

Differential Diagnosis!!navigator!!

Wide variety of clinical presentations lends to numerous differentials. Accurate diagnosis cannot be based on clinical appearance alone (1 study of 345 cases determined 31% error in presumed diagnosis of sarcoid).

  • Occult—infectious folliculitis (dermatophytosis, bacterial), dermatophilosis, pemphigus foliaceus
  • Verrucous—papillomas, developmental hamartomas, SCC
  • Nodular—infections (bacterial, fungal, habronemiasis, pythiosis, hypodermiasis), sterile inflammation (exuberant granulation tissue, foreign body reactions, eosinophilic granuloma), cysts (dermoid, follicular), and other neoplasms (fibroma/fibrosarcoma, melanoma, neurofibroma/sarcoma, cutaneous lymphoma, SCC, and mast cell tumor)

CBC/Biochemistry/Urinalysis!!navigator!!

No specific findings.

Other Laboratory Tests!!navigator!!

N/A

Imaging!!navigator!!

Radiography will reveal no involvement of underlying bone in facial or limb lesions.

Other Diagnostic Procedures!!navigator!!

  • Surface skin cytology and potentially fungal culture are indicated for alopecic lesions to screen for other differentials
  • Fine needle aspiration of nodular lesions may suggest or confirm alternate diagnoses
  • Skin biopsy is needed for definitive diagnosis:
    • Anecdotal reports suggest biopsy may transform occult, verrucous, or nodular forms into more aggressive types. Frequency of such exacerbation is undocumented
    • Biopsy is recommended if treatment will be undertaken once diagnosis is confirmed, and to ensure margins clear for excisional biopsy
    • Important to sample different depths of large lesions—multiple etiologic agents may be concurrent (e.g. exuberant granulation tissue, sarcoid, secondary infection)

Pathologic Findings!!navigator!!

Gross Changes

  • Reflect clinical types, from alopecic to nodular and ulcerated
  • May have smaller satellite lesions surrounding main tumor

Histologic Changes

  • Dermal proliferation of transformed fibroblasts, often with associated epidermal changes
    • Dermis—dominated by proliferation of immature fibroblasts and collagen fibers forming whorls, interlacing bundles, and disorganized arrays
      • Alignment of neoplastic fibroblasts perpendicular to the epidermis in a “picket fence” pattern may occur
      • Neoplastic fibroblasts are spindle-shaped or fusiform with pointed nuclei and large, irregular, pleomorphic nuclei
      • The mitotic rate is usually low
    • Epidermis—hyperkeratosis and acanthosis, with elongated truncated rete ridge projections into dermis, and absence of classical PV changes
    • Differentiation from fibroma or fibrosarcoma may be difficult; PCR testing for BPV may be helpful supportive evidence

Treatment

Outline


TREATMENT

Appropriate Health Care!!navigator!!

N/A

Nursing Care!!navigator!!

Good wound hygiene and fly control before and after surgery.

Activity!!navigator!!

May need restricted activity post surgery depending on body site.

Diet!!navigator!!

N/A

Client Education!!navigator!!

High propensity for recurrence after treatment, and for development of new tumors at new sites. Greatest success in treatment is achieved by close monitoring and prompt additional treatment as required. Observation without treatment is an option for small tumors; however, potential for aggressive growth remains.

Surgical Considerations!!navigator!!

  • Early and complete surgical excision appears optimal whenever possible
  • Conventional surgery most effective (cure rates up to 82%; recurrence rates 50–70%)
    • Tumor margins should be assessed histologically—extension of tumor beyond obvious clinical borders is common
    • Incomplete excision should be promptly followed by reexcision and/or other treatment modalities
    • Surgery combined with another treatment modality may have highest success
  • Cryosurgery may be useful for lesions difficult to excise; however, accurately determining adequate depth of treatment is difficult
  • Laser therapy may also be useful, but has limited availability

Radiation!!navigator!!

Intralesional radiation (brachytherapy) variably effective (cure rates 60–94%), but restricted to accredited institutions.

Medications

Outline


MEDICATIONS

Drug(s) of Choice!!navigator!!

A variety of medical treatments are described with varying success rates. Medical options may be best considered supplementary to surgical excision/debulking, but may have value as sole treatments for small superficial lesions.

Chemotherapy

  • 5-FU
    • Intralesional injections (each 2 weeks; up to 7 times) evaluated in 1 study of occult and verrucous sarcoids, with resolution in 9 of 13 horses; 3 year follow-up
  • Topical cytotoxic agents have anecdotal success (safety and efficacy poorly evaluated)
    • AW-3-LUDES (5-FU/thiouracil/heavy metal salts)
    • XTERRA (Eastern bloodroot and zinc chloride)
    • Animex (blood root extract)
  • Cisplatin—intralesional injections effective (cure rates up to 80%), but exposure risks for administering veterinarians; use restricted to experienced clinicians with appropriate facilities

Immunostimulation

  • Imiquimod 5% gel—applied 3 times weekly
    • Used in small sarcoids (cure in 60% of lesions)
  • Mycobacterial products (commercial whole-attenuated BCG)—intralesional injections (each 2–4 weeks; up to 6 times) with apparent success in periocular sarcoids
  • Autologous vaccines—2 small studies (15 horses); cure rates of ~65%; complications in ~50% (swelling and rare abscessation at implantation sites)

Antiviral

  • Acyclovir (aciclovir) 5% cream (daily for 2–6 months) in 22 horses (cure in 68% of sarcoids)
  • Cidofovir 1% gel (daily for 1 month); effective in 2 sarcoids after surgical debulking

Contraindications!!navigator!!

N/A

Precautions!!navigator!!

  • Severe inflammatory reactions may occur with immunomodulatory therapies. Treatment interruption or reduction in frequency may be needed
  • Anaphylaxis reported with BCG immunotherapy; pretreatment with corticosteroids or diphenhydramine may minimize risk
  • Exposure risks to operators/owners with cytotoxic therapies

Possible Interactions!!navigator!!

None reported.

Alternative Drugs!!navigator!!

N/A

Follow-up

Outline


FOLLOW-UP

Patient Monitoring!!navigator!!

Monitoring closely for recurrence is the prime need, with prompt additional treatment indicated if recurrence occurs.

Prevention/Avoidance!!navigator!!

Fly control/avoidance, good patient hygiene, and good management hygiene practices are anecdotally reported to reduce the incidence of transmission between horses.

Possible Complications!!navigator!!

Related to surgical excision (wound breakdown, restricted movement, wound infections). Interference with performance and cost of treatments may result in requests for euthanasia.

Expected Course and Prognosis!!navigator!!

  • Dependent on number, size, location and invasiveness of tumors—larger and more aggressive forms have a poorer prognosis; single sarcoids have a better prognosis
  • Variable progression—may remain static for years, progress quickly or slowly into more aggressive forms, or spontaneously regress (rare)

Miscellaneous

Outline


MISCELLANEOUS

Associated Conditions!!navigator!!

N/A

Age-Related Factors!!navigator!!

N/A

Zoonotic Potential!!navigator!!

None

Pregnancy/Fertility/Breeding!!navigator!!

N/A

Synonyms!!navigator!!

N/A

Abbreviations!!navigator!!

  • 5-FU = 5-fluorouracil
  • BCG = bacillus Calmette–Guérin
  • BPV = bovine papillomavirus
  • ECA = equine chromosome
  • ELA = equine leukocyte antigen
  • MHC = major histocompatibility complex
  • PCR = polymerase chain reaction
  • PV = papillomavirus
  • SCC = squamous cell carcinoma

Suggested Reading

Bergvall KE. Sarcoids. Vet Clin North Am Equine Pract 2013;29:657671.

Author(s)

Author: Linda J. Vogelnest

Consulting Editor: Gwendolen Lorch

Acknowledgment: The author and editor acknowledge the prior contribution of Sandra Nogueira Koch.

Additional Further Reading

Click here for Additional Further Reading